Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Int J Cancer
; 145(5): 1346-1357, 2019 09 01.
Article
in En
| MEDLINE
| ID: mdl-30807645
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperazines
/
Pyrroles
/
Thiophenes
/
Breast Neoplasms
/
Receptors, Fibroblast Growth Factor
/
Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Int J Cancer
Year:
2019
Type:
Article
Affiliation country:
Germany